Background
==========

In previous studies of concomitant histomorphological changes and antigen retention in Atlantic salmon (*Salmo salar*L.), we showed that intraperitoneal injection with oil-adjuvanted vaccines induces injection-site granulomas \[[@B1],[@B2]\]. The mechanisms underlying the reactions are not well understood. In higher vertebrates, two polar forms of granulomas have traditionally been recognized \[[@B3],[@B4]\]. The first type consists of organized nodular lesions comprising of epithelioid and multinucleate giant cells towards the center of the lesions, surrounded by fibrous tissue. Aggregates of lymphocytes are often present in the periphery. This type of granulomas is associated with a T~H~1 immune response and is dominated by interleukin 12 (IL-12), interferon-γ (IFN-γ), IL-2 and tumor necrosis factor alpha (TNF-α) resulting in macrophage activation and a strong cell-mediated immunity \[[@B5]\]. The second type is characterized by a lack of organization and is a T~H~2 type where IL-4, IL-5 and IL-13 dominate with activation of B cells, eosinophils, mast cells and a strong antibody production \[[@B6]\].

Recently, a third type of CD4 effector T cell lineage, T~H~17, has been discovered following the realization that mice deficient in IFN-γ or its receptor were not resistant to experimental autoimmune encephalomyelitis, an autoimmune disease previously associated with a T~H~1 response \[[@B7]-[@B11]\]. The T~H~17 effector cells are distinct from T~H~1 or T~H~2 types and have a cytokine profile predominated by IL-17A, IL-17F, IL-6, IL-21 and IL-22 (reviewed in ref. \[[@B12]\]). These T cells appear to function in the clearance of pathogens that have not been adequately handled by T~H~1 or T~H~2 cells but have also been implicated in several autoimmune diseases \[[@B13]\].

In mammals, the differentiation of naïve CD4 T helper cells into T~H~17 cells is induced by TGF-β in combination with other cytokines such as IL-6, IL-21 and IL-23 \[[@B14],[@B15]\]. IL-21 also plays an auto-amplification role for T~H~17 cells while IL-23 is essential for stabilization \[[@B16],[@B17]\]. IL-17 (IL-17A) is the hallmark of T~H~17 effector cells whose functions though not fully understood, includes the amplification of the immune response by the induction of other cytokines such as IL-6, TNFα, regulated on activation normal T cell expressed and secreted (RANTES) and monocyte chemoattractant protein-1 (MCP-1) \[[@B18],[@B19]\]. Its capacity to cooperate with cytokines of the innate immunity to promote inflammation suggests that it is a bridge between innate and adaptive responses \[[@B20]\]. IL-17 binds to its receptor (IL-17AR) on target cells resulting in signaling via Act1 or CIKS, TNFR-associated factor 6 (TRAF6) and NF-κB and plays a role in inducing the recruitment of neutrophils and macrophages \[[@B21]-[@B23]\].

In line with the T~H~1/T~H~2 paradigm, the type of macrophage activation has been shown to parallel these responses \[[@B24]\]. In mice, activated macrophages metabolize arginine by two alternative pathways involving the enzymes inducible nitric oxide synthase (iNOS) or arginase \[[@B24]\]. Synthesis of reactive oxygen species (ROS) and NO from L-arginine by iNOS in the so-called classical pathway is associated with the T~H~1 response \[[@B25],[@B26]\]. NO is a crucial host-protective, antimicrobial effector molecule as well as a potential host destructive mediator in diverse settings of immunopathology \[[@B27]-[@B29]\]. On the other hand, metabolism of arginine by arginase in the alternative pathway, converting L-arginine into ornithine and urea \[[@B24]\] is associated with the T~H~2 response. Macrophages in this state of activation play an important role against extracellular pathogens by showing increased phagocytic activity and enhanced gene expression of MHC class II. In addition, alternatively activated macrophages promote proliferation and antibody class switching and function in allergic reactions and wound healing processes \[[@B30]\]. Both iNOS and arginase compete for the common substrate L-arginine and the balance between the two enzymes is competitively regulated by T~H~1 and T~H~2 T helper cells via their secreted cytokines.

In Atlantic salmon, the presentation of granulomas following vaccination with oil-based vaccines is mainly in the form of diffuse granulomatous infiltration of inflammatory cells although in some cases, more organized lesions with lymphocyte infiltrations have been observed. There are, however, very few studies that address inflammatory or immunological reactions at genetic level. It is not certain whether T~H~1/T~H~2/T~H~17 responses exist in salmonids as in mammalian although many cytokines known to drive these responses including IFN-γ have been cloned, sequenced and characterized \[[@B31],[@B32]\]. Interestingly, the different pathways of arginine metabolism in macrophages have been demonstrated \[[@B30],[@B33]-[@B35]\] and more recently, vaccine-associated autoimmunity has also been implicated in Atlantic salmon \[[@B36]\].

Oil-adjuvanted vaccines act through several mechanisms such as the \"depot effect\" where antigens are retained at the injection site and released over extended periods of time; the enhancement of antigen presentation as well as antigen distribution or targeted immune activation \[[@B37]\]. In fish, antigens are retained in granulomas at the injection site \[[@B2]\]. Their distribution to head kidney and spleen following injection has been demonstrated \[[@B38]\]. The head kidney acts as a \'draining lymph node\' for the peritoneal cavity in salmonids \[[@B39]\] and the retention of antigens for months in the head kidney \[[@B38],[@B40]\] demonstrates that this organ plays a role in the immune responses.

In previous studies, we characterized the development of granulomatous reactions following vaccination with oil adjuvanted vaccines both grossly and histopathologically \[[@B2],[@B41],[@B42]\]. In these studies, we demonstrated that different antigens have different capacities to induce inflammation; and that the antigen-adjuvant combinations are responsible for most of the injection-site pathology. We also observed that the severity of inflammatory reactions increased with antigen concentration in the vaccines \[[@B41]\]. In the present study, we have taken advantage of this knowledge to develop skewed models of granulomatous reactions for profiling genes involved in inflammatory and immunological changes. The objective was to identify gene expression profiles associated with mild and severe granulomatous reactions by comparing the patterns in fish injected with standard vaccines inducing mild reactions on one side and those with severe reactions (injected with vaccines containing 6× the antigen concentration) on the other. Gross and histopathological examinations of the pyloric caeca (injection-site), as well as the gene expression profiles of both head kidney tissues and injection site of the same individuals were examined side by side at 3 months post vaccination (when local granulomas are well established \[[@B2]\]) using a salmonid cDNA microarray \[[@B43]\].

Results
=======

Establishment of granulomatous reactions in different groups of fish
--------------------------------------------------------------------

Gross lesions were observed at the injection sites of all fish and were characterized by varying degrees of adhesions with tiny fibrous strands between internal organs such as the pyloric caeca, pancreas and the abdominal wall. Skewed reactions were observed in fish vaccinated with *M. viscosa*vaccines, with mild reactions in FO-7 and severe ones in FO-8 (with a significant difference of p \< 0.01) as demonstrated by the side effects scores (Table [1](#T1){ref-type="table"}). By contrast, only mild reactions with minor differences were observed between FO-1 and FO-2 (*A. salmonicida*) groups. Melaninisation was present in the peritoneal cavities of fish in all groups albeit very mild (results not shown).

###### 

Side effects and inflammatory scores.

  Group   Side effect score\*   Inflammatory score (μm2)
  ------- --------------------- --------------------------
  FO-1    1.5 (1-2)             50 (30)
  FO-2    2 (1-2.5)             590 (340)
  FO-7    2 (1-2.5)             490 (240)
  FO-8    3 (2-4)               3820 (430)

\*Side effects scores of Atlantic salmon following intraperitoneal injection with oil adjuvanted vaccines were graded on a scale of 0-6 and are given as median and range in brackets. Inflammatory scores are represented by means and standard errors in brackets. n = 15.

Microscopically, granulomas in the form of well-circumscribed formations surrounding negative impressions of oil-droplets were observed between the blind sacs of the pyloric caeca, and between the pylorus and the pancreas (Figure [1](#F1){ref-type="fig"}). In mild reactions (FO1, FO-2 and FO-7) the granulomas were small and localized (Figure [1](#F1){ref-type="fig"}). The cellular composition consisted of epithelioid cells with fibroblastic reaction. Lymphocytes, macrophages, mast cells (eosinophilic granule cells) and a few neutrophils were also present (Figure [2](#F2){ref-type="fig"}). In severe reactions (FO-8), more granulomas were observed in each reaction (Figure [3](#F3){ref-type="fig"}). These reactions had similar cellular compositions as mild reactions but with higher numbers of neutrophils, macrophages and lymphocytes (Figure [4](#F4){ref-type="fig"}) being present in the granulomas, but with fewer mast cells.

![**Granulomas at injection-site of Atlantic salmon at 12 weeks following injection**. Well-circumscribed granulomas (G) induced by oil-adjuvanted vaccine containing standard amount of *Moritella viscosa*antigens. Note negative impression of oil droplets (O). Bar = 50 μm.](1471-2164-11-336-1){#F1}

![**Mixed cell infiltrate at injection-site of Atlantic salmon at 12 weeks following injection**. Cellular composition of inflammation consisting of macrophages (M), eosinophilic granular cells or mast cells (EGC), lymphocytes (L) and a few neutrophils (N). Fibroblasts are also distinct (F). Bar = 10 μm.](1471-2164-11-336-2){#F2}

![**Severe inflammatory reaction at injection-site of Atlantic salmon at 12 weeks following injection**. A severe granulomatous reaction with diffuse granulomas (G) induced by vaccine containing 6× standard *M. viscosa*antigens (FO-8). O- negative impression of oil droplets. Bar = 100 μm.](1471-2164-11-336-3){#F3}

![**Cellular composition of severe vaccine granuloma of Atlantic salmon at 12 weeks following injection**. Granulomas constitute of large macrophages (M), several lymphocytes (L), EGCs, and multinucleate cells (MGC). Bar = 15 μm.](1471-2164-11-336-4){#F4}

Microarray results
------------------

523 genes representing 3.3% of the genes spotted on the arrays were differentially expressed in all groups, with very few genes up- or down-regulated in more than one group (Figure [5](#F5){ref-type="fig"}). Differentially expressed genes were classified according to putative functional categories with the aid of Uniprot and NCBI database searches. The assignment of genes to groups was done preferentially to the most specific group. It should be noted however that most of the assignments were based on gene ontology as very few functional studies of these genes have been undertaken in Atlantic salmon.

![**Regulated genes in different groups of Atlantic salmon as determined by microarrays**. FO-2 = *A. salmonicida*(6 × standard concentration - sc); FO-7 = *M. viscosa*(sc); FO-8 = *M. viscosa*(6 × sc).](1471-2164-11-336-5){#F5}

Groups of differentially expressed genes perceived to be of particular interest in this study is listed in Additional file [1](#S1){ref-type="supplementary-material"}. There was a distinct pattern of gene expression in the head kidneys of fish with severe injection site reactions (FO-8) on one side and mild reactions (FO-2 and FO-7) on the other. These genes can be broadly categorized into innate and adaptive immunity. In the FO-8 group, several genes associated with innate immunity were up-regulated in the head kidneys including those encoding humoral defensive proteins such as complement factors and lysozyme C, the most highly expressed in this study (7.1 fold). Others were genes associated with antigen recognition and processing by phagocytes, antigen presentation, cellular signaling including CC chemokine and leukocyte cell derived chemotaxin 2 (LECT-2), matrix and cellular differentiation, anti-oxidative stress and inflammation. In contrast, very few of these genes were expressed in FO-7 or FO-2.

As for genes associated with adaptive immunity, clones of membrane-bound and soluble forms of IgM were up-regulated in FO-8 while several others associated with T lymphocytes such as T-cell receptor alpha chain, signaling lymphocyte activation molecule-associated protein, Tyrosine kinase ZAP-70 and Thymus-specific serine protease precursor were down regulated. Only one clone of IgM heavy chain was up-regulated in FO-7 while none were observed in FO-2.

As might be expected, a significant number of up-regulated genes were involved in transcription/translation and metabolism (18.8%). Some unknown genes (16.6%) were up-regulated, mostly in FO-8 while 22.6% were down-regulated, mostly in FO-2. 50.9% of the genes could not be clearly classified into inflammatory and immune responses (Additional file [2](#S2){ref-type="supplementary-material"}).

Validation of microarray results by real-time qPCR
--------------------------------------------------

Twenty-six genes identified by microarrays as differentially regulated were validated by real-time qPCR. Their selection was based on their putative roles in granulomatous inflammation. A few additional genes were randomly selected and validated by real-time qPCR for representational purposes. In the FO-8 group, gene expression results by microarrays were confirmed by qPCR (88%). Lesser agreement was observed between the two platforms in FO-7 (54%) and FO-2 (61%) groups.

qPCR results for individual genes like Annexin A1, C1q-like, lysozyme and C6 were found significantly higher expressed in FO8 groups compared to the others (Figure [6](#F6){ref-type="fig"}). Similarly genes associated with antigen recognition and processing by phagocytes (cathepsin D), antigen presentation (CD209) (Figure [7](#F7){ref-type="fig"}), cellular signaling including CC chemokine and leukocyte cell derived chemotaxin 2 (LECT-2) were similarly upregulated (Figure [8](#F8){ref-type="fig"}). Both membrane and secreted forms of IgM were verifiably up-regulated in FO-8 compared to other groups (Figure [9](#F9){ref-type="fig"}). Some T cell related genes such as lymphocyte cytosolic protein 1 and signaling lymphocyte activation molecule, though down-regulated in microarrays, were not differentially expressed (not shown).

![**Markers of inflammation expressed in the head kidney of Atlantic salmon injected with different oil-based vaccines**. Quantitative real-time RT-PCR (qPCR) expression of genes identified as upregulated by microarray. FO-1 = *A. salmonicida*(sc); FO-2 = *A. salmonicida*(6 × sc); FO-7 = *M. viscosa*(sc); FO-8 = *M. viscosa*(6 × sc). Gene expression ratios normalized to Elongation factor 1α (EF1α). Error bars = standard error (SE), n= 7. \*p \< 0.05.](1471-2164-11-336-6){#F6}

![**Antigen processing and presentation genes expressed in the head kidney of Atlantic salmon injected with different oil-based vaccines**. qPCR expression studies of C-type lectin receptor (CLR), antigen recognition and processing by phagocytes (cathepsin D) and antigen presentation (CD209) genes identified as upregulated by microarray. FO-1 = *A. salmonicida*(sc); FO-2 = *A. salmonicida*(6 × sc); FO-7 = *M. viscosa*(sc); FO-8 = *M. viscosa*(6 × sc). Gene expression ratios normalized to EF1α. Error bars = SE, n= 7. \*p \< 0.05.](1471-2164-11-336-7){#F7}

![**Cellular signaling and chemotaxin markers expressed in the head kidney of Atlantic salmon injected with different oil-based vaccines**. qPCR expression studies of chemokine (CC) and leukocyte cell derived chemotaxin 2 (LECT 2) genes identified as upregulated by microarray. FO-1 = *A. salmonicida*(sc); FO-2 = *A. salmonicida*(6 × sc); FO-7 = *M. viscosa*(sc); FO-8 = *M. viscosa*(6 × sc). Gene expression ratios normalized to EF1α. Error bars = SE, n= 7. \*p \< 0.05.](1471-2164-11-336-8){#F8}

![**Immunoglobulin genes expressed in the head kidney of Atlantic salmon injected with different oil-based vaccines**. qPCR expression studies of IgM and immunoglobulin heavy chain constant region (IGHC) genes identified as upregulated by microarray. FO-1 = *A. salmonicida*(sc); FO-2 = *A. salmonicida*(6 × sc); FO-7 = *M. viscosa*(sc); FO-8 = *M. viscosa*(6 × sc). Gene expression ratios normalized to EF1α. Error bars = SE, n= 7. \*p \< 0.05.](1471-2164-11-336-9){#F9}

Profiling of inflammatory and immune genes
------------------------------------------

Arginase 1 (p \< 0.05), IL-17A (p = 0.007) and IL-17A-receptor (AR) (p = 0.009) were significantly up-regulated in FO8 compared to all other groups (Figures [10](#F10){ref-type="fig"} and [11](#F11){ref-type="fig"}). TGF-β was significantly up-regulated in FO-8 compared to FO-1 (p = 0.001), with a similar general trend in the strength of expression in different groups as the severity of lesions (Figure [11](#F11){ref-type="fig"}, Table [1](#T1){ref-type="table"}). No difference was observed in the expressions of the genes encoding IFN-γ, CD4, CD8, IL-6 receptor, IL-10, iNOS, GATA-3 and Granzyme A between groups (not shown).

![**Arginase and IL17AR genes expressed in the head kidney of Atlantic salmon injected with different oil-based vaccines**. qPCR expression studies of arginase and IL17A receptor (IL17AR) identified as upregulated by microarray. FO-1 = *A. salmonicida*(sc); FO-2 = *A. salmonicida*(6 × sc); FO-7 = *M. viscosa*(sc); FO-8 = *M. viscosa*(6 × sc). Gene expression ratios normalized to EF1α. Error bars = SE, n= 7. \*p \< 0.05.](1471-2164-11-336-10){#F10}

![**Cytokine genes expressed in the head kidney of Atlantic salmon injected with different oil-based vaccines**. qPCR expression studies of IL17A and transforming growth factor β (TGF-β) genes identified as upregulated by microarray. FO-1 = *A. salmonicida*(sc); FO-2 = *A. salmonicida*(6 × sc); FO-7 = *M. viscosa*(sc); FO-8 = *M. viscosa*(6 × sc). Gene expression ratios normalized to EF1α. Error bars = SE, n= 7. \*p \< 0.05.](1471-2164-11-336-11){#F11}

Discussion and conclusions
==========================

Several genes including complement factors C1q and C6, mannose binding protein, lysozyme C, C-type lectin receptor, CD209, Cathepsin D, CD63, LECT-2, CC chemokine and IgM were identified in the head kidney as associated with severe injection-site granulomatous reactions in this study. The expression of these genes corresponds with gene profiles of an active inflammation \[[@B44]-[@B47]\] and corroborate previous reports that vaccine-based granulomas are associated with a chronic, active inflammation \[[@B2]\]. Furthermore, the finding that IL-17A and its receptor (IL-17AR) representing T~H~17 cells were up-regulated in fish with severe reactions while none of the genes directly reflective of T~H~1 T cell lineage (IFN-γ, CD4) or T~H~2 (GATA-3) differentiation were differentially expressed is interesting in light of the involvement of the T~H~17 cells in autoimmune responses \[[@B13]\].

Chronic, active inflammation is consistent with the presence of neutrophils and macrophages at the injection site of FO-8. In this group, genes encoding LECT-2 and CC chemokine were verifiably up-regulated in head kidney indicating an active inflammatory process in the \"draining lymph node.\" Further to this, the up-regulation of mRNA transcripts of complement factors C1q and C6, mannose binding protein, lysozyme C, innate cell-associated proteins of the C-type lectin receptors, CD209, Cathepsin D and CD63, anti-oxidative genes such as metallothionein and oxidative stress-related genes are additional indications of active inflammatory processes \[[@B48]\] in fish with severe granulomatous reactions.

Another intriguing result was the finding that *M. viscosa*(FO-7&8) is more pro-inflammatory than *A. salmonicida*(FO-1&2). In natural infection, lethality of these pathogens is in the reverse \[[@B49]\]. The cause of the difference in this study is not clear but it is not unlikely that the structure or quantity of pathogen-associated molecular patterns (PAMPs) \[[@B50]\], or even the orientation/presentation of antigens on the surface of oil droplets may be responsible. The importance of the different factors can only be solved in future studies.

Macrophages are the main cell type responsible for the uptake, breakdown, removal or sequestration of antigens. For an effective response, appropriate activation is necessary. The observed expression of arginase in this study is consistent with macrophages activated through the alternative pathway and is indicative of a T~H~2 response \[[@B51]\]. In humans, it has been documented that T~H~2 cytokines bias responses towards inadequate activation of macrophages resulting in less efficient control of *Mycobacterium leprae*infections and high bacterial counts inside granulomas leading to diffuse spreading of the infection \[[@B52]\]. To what extent macrophage activation plays a role in clearing of the vaccine antigens in salmonids is not known in detail. It is not possible to deduce from the results of this study whether the alternative macrophage activation pathway is an appropriate response but this should be a subject of further investigation.

The massive up-regulation of IgM mRNA transcripts in the head kidneys of fish with severe injection-site reactions (Additional file [1](#S1){ref-type="supplementary-material"}) is suggestive of a strong humoral response, another indication of a T~H~2 response consistent with reports of others \[[@B53],[@B54]\]. It must be noted however that no tests to examine the specificity of antibodies were conducted in this study. It is thus unknown whether the bulk of the IgM mRNA transcripts detected in this study are indications of responses against vaccine-related antigens or if they were directed at self (autoimmune) antigens. Autoimmunity has previously been suggested as one of the etiologies of vaccine associated side effects in Atlantic salmon \[[@B36]\].

In fish with mild injection-site reactions, microscopic examinations revealed a process of wound healing. Mast cells and macrophages were observed in abundance at the injection site of fish in these groups (FO-1, FO-2 and FO-7). These cells have previously been associated with granulomatous reactions \[[@B2],[@B55]\] and wound healing \[[@B42]\], although they have also been associated with the initiation of inflammation in Atlantic salmon \[[@B56]\]. In higher vertebrates T~H~2 responses have been shown to play an important role in wound healing \[[@B57]\] with mast cells producing or influencing the production of IL-4 and IL-10 tipping the response towards T~H~2 \[[@B58],[@B59]\]. In the present study, no significant differences in the expression of GATA-3 or IL-10 were observed between different groups. Similarly, no differences were observed for IL-12, IFN-γ, CD4, CD8 and Granzyme A. As similar antigen preparations per pair of vaccines were used differing only in concentrations, the anticipation is that similar T~H~responses drove the inflammatory responses in all groups; the difference in severity being motivated by antigen concentration and determined mainly by the innate response.

Interestingly, the expression of IL-17A and its receptor showed similar trends as the severity of inflammatory profiles (Figures [10](#F10){ref-type="fig"} and [11](#F11){ref-type="fig"}, and Table [1](#T1){ref-type="table"}), being significantly up-regulated (p = 0.007 and 0.009, respectively) only in the group with severe granulomas. IL-17A is a pro-inflammatory cytokine produced predominantly by activated T cells. It acts through its receptor IL-17AR which, although ubiquitously expressed, its main responses in higher vertebrates are found in epithelial cells, endothelial cells, fibroblasts, macrophages and dendritic cells (reviewed in ref. \[[@B60],[@B61]\]). It is an essential component of the IL-17A signaling whose induction is required for effective responses \[[@B60],[@B62]-[@B64]\]. It has also been demonstrated to be up-regulated together with IL-17A in autoimmune diseases \[[@B65]-[@B67]\]. IL-17A expression induces the production of an array of cytokines and metalloproteases by fibroblasts, endothelial cells, macrophages and epithelia cells resulting in the induction of inflammation and recruitment of neutrophils \[[@B68]\]. These findings suggest that IL-17A/IL-17AR and therefore the T~H~17 response contributes to the induction of severe side effects in line with the higher number of infiltrating neutrophils and macrophages in this group. To what extent autoimmunity as previously reported \[[@B36]\] is involved in these responses remains elusive as the presence of autoantibodies was not assessed in this study.

The involvement of TGF-β in severe granulomatous reaction in this study is compelling given the expression patterns exhibited in different groups (Figure [11](#F11){ref-type="fig"}) relative to the degree of side effect lesions (Table [1](#T1){ref-type="table"}). In mammals, the expression of TGF-β has previously been associated with the recruitment of polymorphonuclear cells to inflammatory sites \[[@B69]\]. Together with IL-6, IL-21 or IL-23, it has also been demonstrated to be essential in the commitment of naïve T cells into T~H~17 cells \[[@B14],[@B15]\]. TGF-β is produced by cells of the innate immune system \[[@B70]\] as well as regulatory T cells (T-regs) \[[@B71],[@B72]\]. Although only the receptor for IL-6 and not the cytokine itself was examined in the present study and found not to be induced, it is not unlikely that a different expression pattern would have been observed with the latter. On the other hand, this finding may suggest that other cytokines such as IL-21 or IL-23 act in concert with TGF-β to regulate T~H~17 cells in the induction of severe granulomatous reactions in Atlantic salmon.

The screening of differentially expressed genes for granulomatous reactions using microarrays in this study was done by examining head kidney tissues rather than the injection site. It is conceivable that more inflammatory genes would be up- or down-regulated at the latter compared to the former, as most inflammatory genes are known to act locally. In i.p. vaccinated fish, the injection site is the abdominal cavity and vaccine components localize primarily at the pyloric caeca/pancreas area \[[@B2],[@B41]\]. Because of the anatomical co-localization of the pylorus with the pancreas, collection of homogeneous tissue for gene expression studies is problematic. An alternative approach would be to vaccinate the fish intramuscularly and examine gene expression at the injection site as previously reported \[[@B73]\]. However, for vaccines routinely administered i.p., this approach would have to be weighed against the prospect of modifying the immune response since different routes of vaccination are known to influence the resulting T~H~profiles \[[@B74]\].

In conclusion, the profile of the immune responses as assessed by gene expression to oil-adjuvanted vaccines in Atlantic salmon is strongly influenced by antigen content and also the type of antigens included in the vaccine preparation. There is a variation in the response along an axis of a chronic, active inflammation on one end to mild inflammation and wound healing on the other. Gene expression patterns indicative of neutrophil persistence and macrophage activation are biased towards a mixed reaction between T~H~2 and T~H~17 profiles in the head kidney.

Methods
=======

Fish
----

About 250 Atlantic salmon (*Salmo salar*L; Bolax strain) weighing approximately 42 g each were procured from Lindås Fiskeoppdrett AS, Vågseidet in Norway. The fish were reared in continuously running fresh water tanks at Stiftelsen Industrilaboratoriet Høyteknologisenteret (ILAB) in Bergen, Norway. The water temperature was 17°C on average and the fish were fed on commercial dry pellets (EWOS Innovation, Bergen, Norway).

Vaccines
--------

Injection preparations used in this study are shown in Table [2](#T2){ref-type="table"}. All preparations were bivalent experimental vaccines (with equal concentrations of infectious pancreatic necrosis virus in all vaccines as second antigens) from PHARMAQ AS, Overhalla, Norway, produced according to in-house standard procedures. The oil-based antigen preparations were formulated as water-in-oil (w/o), where the water phase (containing bacterial antigens) was dispersed into an oil phase (continuous phase containing emulsifiers and stabilizers). Emulsification of the antigens with adjuvant was done using a homogenizer with a standard emulsification stator/rotor connected to an emulsior screen. The potency of the standard vaccines was according to specifications given in European Pharmacopoeia monographs for *Aeromonas salmonicida*, RPS \> 80 and for *Moritella viscosa*the potency was RPS \> 60 and 60% control mortality in the non-vaccinated (according to internal standards of PHARMAQ). Sterility, free formaldehyde, inactivation, stress, viscosity and droplet size tests were all performed and standardized on blended bacterin according to standard procedures in the laboratory.

###### 

Vaccine preparations used in the present study.

         Antigens                     
  ------ ---------------------------- ----------------------------
  FO-1   Standard concentration       0
  FO-2   6 × standard concentration   0
  FO-7   0                            Standard concentration
  FO-8   0                            6 × standard concentration

\*All vaccines were adjuvanted with mineral oil and were formulated as water-in-oil emulsions.

Randomisation, marking and vaccination of the fish
--------------------------------------------------

The selection of fish was done by dip-netting followed by sequential allocation into groups. Four groups comprising 50 fish each were included in the present experiment. Marking was done by fin clipping. Prior to marking, the fish were anaesthetised using Chlorobutanol (Sigma, Steinheim, Germany) dissolved in rearing water at a concentration of 0.5 ml/L. The fish were vaccinated by injecting 0.1 ml of vaccine intraperitoneally (i.p.) through the ventral midline, about 1 to 1.5 pelvic fin lengths anterior to the pelvic fin base. Self-refilling syringes (Socorex, Ecublens, Switzerland) with 0.6 × 3 mm needles (Unimed, Lausanne, Switzerland) were used. After immunization, all the fish were placed into two fiberglass tanks, each with a water capacity of 500 L. Post vaccination mortality and appetite of the fish were monitored daily.

Sample collection and processing
--------------------------------

Sampling was done at 12 weeks post vaccination (p.v.). Fifteen fish from each group were randomly selected by dip netting, anaesthetized and then sorted into groups. Sampling was done as previously described \[[@B2]\]. Briefly, the fish were stunned by a blow to the head and the gill vein severed. A sample (max volume = 10 × 10 × 5 mm) of pyloric caeca and surrounding tissues (designated as the injection site) and head kidney were collected from each fish and stored in 10% phosphate buffered formalin for a minimum of 4 days. Thereafter, the samples were processed according to standard procedures employed for hematoxylin and eosin (H&E) staining. In addition, parallel samples of the head kidney and pyloric caeca were collected from individual fish and stored separately in RNA*later*^®^(QIAGEN, Hilden, Germany) according to the manufacturer\'s instructions until required.

Assessment of gross and microscopic lesions
-------------------------------------------

Gross lesions in the peritoneal cavity of the fish were graded on an arbitrary scale of 0-6, where 0 = no lesions and 6 = severe as previously described \[[@B75]\]. For microscopic lesions, the size of inflammatory reaction of each fish was assessed by calculating the area of the inflamed lesions using computer-assisted microscopy on H&E stained sections as previously described \[[@B41]\]. Briefly, well-calibrated microscopical images were acquired at 100 × magnification by using a computer-controlled digital camera mounted on a light microscope. The circumferences of inflamed areas in digital images were marked manually. The number of pixels within the marked region was then converted to area with the help of the Image-Pro^®^Analysis program (Media Cybernetics, L.P., Silver Spring, USA).

Data on gross lesions was subjected to Fisher\'s exact test while inflammatory reactions between groups were analysed by linear regression as previously described \[[@B42]\].

Microarray-based screening of gene transcripts in head kidney tissues
---------------------------------------------------------------------

Head kidney tissues, rather than those of the injection site (pylorus/pancreas) were used for the screening of gene transcripts by microarrays in this study due to the difficulty in obtaining homogeneity in the samples of the latter as the organs (pyloric caeca and pancreas) are anatomically intertwined. Because of this it was perceived that using injection site tissues would not give representative gene expression results.

RNA isolation
-------------

RNA from head kidney tissues stored in RNA*later*was isolated by using the RNeasy^®^minikit (QIAGEN, Hilden, Germany). Each tissue was homogenized by subjecting it to a mixer mill MM301 (Retsch GmbH & Co., Haan, Germany) for 2 min at 20 Hz in buffer RLT followed by total RNA extraction with on-column DNAse treatment according to the manufacturer\'s protocol to minimize DNA contamination. The quantification of RNA, purity and integrity assessment were done by using a NanoDrop ND-1000 spectrophotometer (NanoDrop technologies, Inc., Wilmington, USA) and the Agilent 2100 Bioanalyzer (Agilent technologies).

Microarray study design and target preparation
----------------------------------------------

Fish were grouped according to the vaccines administered (Table [2](#T2){ref-type="table"}). The group with the least gross and inflammatory changes (FO-1) was used as the reference in microarray experiments. Out of 15 fish sampled in each group, only total RNA from 12 fish, chosen on the basis of abundance and quality/integrity, was used for downstream analysis (Figure [12](#F12){ref-type="fig"}).

![**Microarray study design**. Total RNA from 12 fish in each group was subdivided into pools of 4 fish each and subsequently used for hybridization. Vaccine A represents the reference group (FO-1 *A. salmonicida*standard concentration).](1471-2164-11-336-12){#F12}

RNA amplification
-----------------

In order to generate sufficient amounts of targets for hybridization, each total RNA pool was subjected to one round of amplification using the Amino Ally MessageAMP™ II aRNA amplification kit (Ambion, Austin, USA) starting with 2 μg. Briefly, reverse transcription (RT) to synthesize the first cDNA strand was done using oligo(dT) primers containing a T7 promoter sequence. The RNA and primer mix was first denatured at 70°C for 10 min prior to the addition of the RT master mix. The first strand synthesis reaction was incubated at 42°C for 2 hrs. The second cDNA strand was synthesized by the addition of the second strand master mix and incubated at 16°C for 2 hrs. The resulting double stranded cDNA was purified by using column-based reagents, according to the protocol supplied with the kit. Finally, amino allyl-modified anti-sense RNA (aRNA) was synthesized by the addition of an *in-vitro*transcription master mix containing a 1:1 ratio of UTP to amino allyl-modified UTP and held at a temperature of 37°C for 14 hrs. The aRNA was then purified and stored at -80°C until required.

Coupling of aRNA was done with either Cy3 or Cy5 dye according to the Amino Ally MessageAMP™ II aRNA Amplification Kit protocol with minor modifications. Briefly, one vial of Cy3 or Cy5 monofunctional reactive dyes (Amersham, Buckinghamshire, UK) was resuspended in 22 μl of DMSO prior to coupling. 3 μg of aRNA was dried to completion in a vacuum centrifuge (Savant Instruments, Inc., Farmingdale, NY). The aRNA was resuspended in 4.5 μl of coupling buffer. Thereafter, 5.5 μl of dye was added to the aRNA:coupling buffer and incubated for 30 min in the dark. 2.25 μl of 4 M hydroxylalamine was then added to quench the reaction followed by 12.75 μl of water to obtain a total volume to 30 μl. Dye labeled aRNA purification was done according to the manufacturer\'s instructions.

Array hybridization, scanning and analysis
------------------------------------------

The fabrication of the salmonid microarrays used in the present study is described elsewhere \[[@B43]\]. A complete description and list of the probes used on the arrays is available at <http://web.uvic.ca/grasp>.

The experiments were designed to comply with MIAME guidelines \[[@B76]\]. Three biological and 2 technical replicates (dye-swapped) were utilized in different combinations to hybridize to 18 arrays (Figure [12](#F12){ref-type="fig"}). The assignment of microarrays to treatment groups for hybridization was done randomly by using a random number generator. To minimize technical variability, target synthesis and hybridizations were done in batches of 6 where all treatment groups were equally represented.

Post-print processing of arrays was done by washing 2 × 5 min in 0.2% SDS, 5 × 1 min in MilliQ water followed by immersion in MilliQ water at 100°C for 3 min. The slides were dried by centrifugation at 512 × g for 5 min.

Array were prehybridized by placing them in (5 × SSC, 1% SDS and 3% BSA (Sigma, Steinheim, Germany)) and incubating at 49°C in a water bath for 11/2 hrs. Thereafter, the arrays were washed thrice for 20 sec in MilliQ water and dried by centrifugation as above. For hybridization, 500 ng of labeled target reconstituted to a final volume of 26 μl, 30 μL of 2 × formamide hybridization buffer (Genisphere, Hartfield, USA) and 4 μl LNT dT blocker were used. Hybridization was done at 49°C in a water bath for 16 hrs. The arrays were washed first in 2 × SSC, 0.1% SDS for 10 min at 49°C, 2 × 5 min in 2 × SSC, 0.1% SDS at room temperature, 2 × 5 min in 1 × SSC, 4 × 5 min in 0.1 × SSC followed immediately by centrifugation at 512 × g for 5 min.

Imaging was done at 10 μm resolution using ScanArray™ Express microarray scanner (Packard Bioscience). The Cy3 and Cy5 cyanine fluors were excited at 543 nm and 633 nm, respectively, at the same laser power (90%), with adjusted photomultiplier tube settings between slides to balance the Cy3 and Cy5 channels. Image analysis and fluorescent intensity data was extracted from Tiff images using ImaGene™ 5.6 Standard Edition software.

Data analysis (correction of background, setting of background corrected values \< 0.01 to 0.01), normalization (Lowess) and analysis (formation and manipulation of fold change transcript lists) were performed in GeneSpring Gx (Agilent Technology). Clones were assigned as either up or down regulated based on two conditions: a ratio of at least 1.5 fold change in at least 3 of the six replicates and also a statistical p value of \< 0.05. The data is deposited at NCBI\'s GEO repository under accession number **GSE8826**and Platform **GPL2716**.

Validation of microarray results by quantitative RT-PCR
-------------------------------------------------------

The results obtained by microarray experiments were verified by real-time quantitative PCR (qPCR) by using the LightCycler 2.0 instrument and LightCycler^®^FastStart DNA Master^PLUS^SYBR Green I (Roche Diagnostics GmbH, Manheim, Germany) as previously described \[[@B77]\].

One microgram of total RNA from the head kidney or pyloric caeca of individual subjects was reverse transcribed using oligo (dT)~20~and Superscript III Reverse transcriptase (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s instructions. Thereafter, cDNA was scaled up to 100 μl with water. Two microlitres of the diluted cDNA was used as template for each qPCR reaction.

The primers employed in the quantification of PCR reactions are presented in Table [3](#T3){ref-type="table"}. Designing of the primers was done using Primer3 software (Whitehead Institute of Biomedical Research, MA., USA) while primers were procured from MWG Biotech AG, Germany. The generation of a single product of the expected size for each assay was confirmed by electrophoresis of the PCR (ordinary) and also LightCycler q-PCR product on a 2% agarose gel. Quantitative PCR was done in duplicate and the melting curve analysis was applied to confirm the formation of a single product.

###### 

Primers used for real-time quantitative PCR.

  **Accession no**.   Name                                                             Direction   Sequence                   **T\***~**A**~   P\*\* size (bp)
  ------------------- ---------------------------------------------------------------- ----------- -------------------------- ---------------- -----------------
  **CB510337**        T cell receptor alpha chain (TCAC)                               Fwd         GCCTGGCTACAGATTTCAGC       66               107
                                                                                       Rev         GGCAACCTGGCTGTAGTAGC                        
                                                                                                                                               
  **CA052383**        Complement component C6                                          Fwd         TCCAACGTGCCACTCTCCTC       64               131
                                                                                       Rev         CCGAACAGGGCTTCTACACC                        
                                                                                                                                               
  **CA044561**        L-plastin (Lymphocyte cytosolic protein 1)                       Fwd         CATGCGAACACAGTCAGAACC      62               111
                                                                                       Rev         CAACGCCAAGTACGCTATCAC                       
                                                                                                                                               
  **CA059313**        Annexin A5                                                       Fwd         GAAACTTCAACGCCAACCAAG      60               115
                                                                                       Rev         TGTCTCTGGCTGTTGCTACG                        
                                                                                                                                               
  **CA062753**        SH2 domain protein 1A                                            Fwd         GGGAGTAGTCTCTGCTGTCC       62               95
                                                                                       Rev         GGCTCTACTGCCTCTGTGTG                        
                                                                                                                                               
  **CB493440**        Proteasome subunit alpha type 4                                  Fwd         GTTCTAACCAATGAGCTGAGG      60               89
                                                                                       Rev         AACGCTGTCACCAACTGCTC                        
                                                                                                                                               
  **CB511680**        Lysozyme C                                                       Fwd         CACCGACTATGGCATCTTCC       58               129
                                                                                       Rev         CTGACCGCCACTGTGATGTC                        
                                                                                                                                               
  **CA767935**        Cathepsin D                                                      Fwd         CAGGCTGGTAAGACCATCTGC      58               127
                                                                                       Rev         TGTTGTCACGGTCGAACACAG                       
                                                                                                                                               
  **DN048269**        Complement C3a                                                   Fwd         GAGGAAAGGTGAGCCAGATG       58               106
                                                                                       Rev         TGTGTGTGTCGTCAGCTTCG                        
                                                                                                                                               
  **CA043655**        Interferon regulatory factor-1 (IRF-1)                           Fwd         GATGGGACCTGAACAAGGATG      58               132
                                                                                       Rev         GAAGGGAGTTCATTGCACAGC                       
                                                                                                                                               
  **A064221**         MHC-II alpha                                                     Fwd         GAACACAGCAGGACCCACAC       58               134
                                                                                       Rev         TCTCCAGTCTGCCCTTCACC                        
                                                                                                                                               
  **CX984314**        Leukocyte cell derived chemotaxin (LECT-2)                       Fwd         GCGAGATGGTCAAGTTTGGTC      58               115
                                                                                       Rev         TGATGCTCACGGTTTCCTCTG                       
                                                                                                                                               
  **CK991004**        Immunoglobulin heavy chain constant region (IGHC)                Fwd         AGATGGACGCTTGTGGATCTC      58               118
                                                                                       Rev         GGTCTGGAGCAATGGGACAG                        
                                                                                                                                               
  **CB488287**        Secreted protein acidic and rich in cysteine precursor (SPARC)   Fwd         CCAGCAGGTCCAGGGAGTG        60               156
                                                                                       Rev         TGCGTATGAGGGACTGGCTG                        
                                                                                                                                               
  **CA055453**        Glutathione peroxidase                                           Fwd         GCAATCAGTTCGGACATCAGG      60               131
                                                                                       Rev         GTCCTTCCCATTCACATCCAC                       
                                                                                                                                               
  **CA050443**        C1q-like adipose specific protein                                Fwd         GTGATGACATTTTTGAAGATCAGG   60               104
                                                                                       Rev         AATAAGGAGAGAATGAAGGTGATC                    
                                                                                                                                               
  **CB516930**        CD209 antigen                                                    Fwd         CCCATCTCCAATCCCCTTCC       60               119
                                                                                       Rev         CCTGCACAGCAAGGAACAGC                        
                                                                                                                                               
  **CA051187**        Mannose-binding protein C precursor                              Fwd         CAAGAGGGGCTTGGTGTTGG       60               107
                                                                                       Rev         TGTTGTCAACATTGAGCCATGC                      
                                                                                                                                               
  **CA039888**        IgM heavy chain membrane bound form                              Fwd         TCTGGGTTGCATTGCCACTG       60               121
                                                                                       Rev         GTAGCTTCCACTGGTTTGGAC                       
                                                                                                                                               
  **CB492684**        Annexin A1                                                       Fwd         AGGAAGGGAACAGACTGCTC       60               120
                                                                                       Rev         AATAGCCTTTGCCACATCCAC                       
                                                                                                                                               
  **CB503743**        CC chemokine (CCL 19)                                            Fwd         CCATGTAGCAGCAAGCACAG       66               128
                                                                                       Rev         GGCAGCTATCCGACATCCTC                        
                                                                                                                                               
  **CB510333**        Cd 63                                                            Fwd         AACAGTCTGACACCCCATCTG      58               97
                                                                                       Rev         TGTGCCAGACTCCTGCTGTG                        
                                                                                                                                               
  **CA056108**        C type Lectin receptor A (CTL)                                   Fwd         ATCCTGCACAGCAAGGAACAG      58               128
                                                                                       Rev         TTGTCCACCCATCTCCAATCC                       
                                                                                                                                               
  **CK990996**        Metallothionine                                                  Fwd         GGACAGCAGGGGCAGCAAC        58               128
                                                                                       Rev         GCGATCAAAAACTGGAACATGG                      
                                                                                                                                               
  **CA058146**        Putative complement factor D                                     Fwd         GAATCCATCGGCTGTACGAAG      64               115
                                                                                       Rev         CCGTTGGTGTGTAATGGGATG                       
                                                                                                                                               
  **AY693393**        CD8α                                                             Fwd         CACTGAGAGAGACGGAAGACG      56               174
                                                                                       Rev         TTCAAAAACCTGCCATAAAGC                       
                                                                                                                                               
  **DQ867018**        CD4                                                              Fwd         GAGTACACCTGCGCTGTGGAAT     58               123
                                                                                       Rev         GGTTGACCTCCTGACCTACAAAGG                    
                                                                                                                                               
  **FJ263446**        Interferon gamma (IFN-γ)                                         Fwd         CTAAAGAAGGACAACCGCAG       60               159
                                                                                       Rev         CACCGTTAGAGGGAGAAATG                        
                                                                                                                                               
  **AF088999**        Inducible nitric oxide sythase (iNOS)                            Fwd         GGAGAGCCTTCTGGTTG          60               116
                                                                                       Rev         ACCTTAACTTGTTCCTGAGATAC                     
                                                                                                                                               
  **EF165028**        IL-10                                                            Fwd         CGCTATGGACAGCATCCT         59               84
                                                                                       Rev         AAGTGGTTGTTCTGCGTT                          
                                                                                                                                               
  **BK001401**        Arginase 1b                                                      Fwd         CATTGGCTTGAGAGACGTGGAT     60               68
                                                                                       Rev         AGTAACCTTTGACACCCAGCAA                      
                                                                                                                                               
                      Arginase 1b (Probe)                                                          6FAM-CAGAAGAGCACCATATCC                     
  **AF321836**        Elongation factor-1                                              Fwd         GCTGTGCGTGACATGAGG         60               88
                                                                                       Rev         ACTTTGTGACCTTGCCGC                          
                                                                                                                                               
  **EU418015**        GATA-3                                                           Fwd         CCCAAGCGACGACTGTCT         60               61
                                                                                       Rev         TCGTTTGACAGTTTGCACATGATG                    
                                                                                                                                               
                      GATA-3 (Probe)                                                               FAM-TTCCTGCCCGTCTTGC                        
  **BT048013**        Granzyme A                                                       Fwd         GACATCATGCTGCTGAAGTTG      60               81
                                                                                       Rev         TGCCACAGGGACAGGTAACG                        
                                                                                                                                               
  **BT059144**        IL-6 receptor                                                    Fwd         TCCCTCAGTGCTACCTCCTC       60               138
                                                                                       Rev         CCAGGTGTGGCTCTCTACTC                        
                                                                                                                                               
  **GW574233**        IL-17A                                                           Fwd         TGGTTGTGTGCTGTGTGTCTATGC   60               136
                                                                                       Rev         TTTCCCTCTGATTCCTCTGTGGG                     
                                                                                                                                               
  **BT058869**        IL-17A receptor                                                  Fwd         CAAGTGGAGGGCGATGTGTG       60               107
                                                                                       Rev         TCGGGCAGGAAGAGGTTGAG                        
                                                                                                                                               
  **EU082211**        TGF-β                                                            Fwd         AGTTGCCTTGTGATTGTGGGA      60               191
                                                                                       Rev         CTCTTCAGTAGTGGTTTGTCG                       

\* Annealing temperature; \*\*Product

Data analysis was done by using the LightCycler software version 4.0. The second-derivative maximum calculation was used to determine the crossing point (Cp). Since the focus was relative expression, the calibrator-normalized relative gene expression (Elongation factor 1α as the reference gene) without efficiency correction was employed for analysis. For statistical purposes, relative gene expression ratios were normalized by log transformation. Linear regression analysis was then performed with the help of STATA™ SE 9 for windows (Stata Corp. College station, TX, USA). The gene expression ratios were taken as response variables while the vaccination groups were defined as dummy variables.

To further characterize the immunological responses driving granuloma formation, the expression of additional genes not found on the microarrays including IFN-γ, IL-6 receptor, IL-10, TGF-β, IL-17A, IL-17A-receptor (IL17-AR), CD4, CD8 and iNOS was done as already described above. For arginase 1, an MGB probe (Applied Biosystems, Warrington, UK) and primers designed to anneal at the splice site were used in combination with the LightCycler^®^Taqman^®^Master reagents on the LightCycler instrument. A two-step PCR program (95°C for 10 sec; 60°C for 1 min) was utilized. For GATA-3, a Taqman probe in combination with LightCycler reagents as described above was used. All primer sequences are presented in Table [3](#T3){ref-type="table"}.
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###### Additional file 1

**Gene expression profiles by vaccine groups**. Presents a comparison of gene expression profiles between different groups of fish, categorized according to putative gene function.
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###### Additional file 2

**Non-immune gene differentially regulated**. Presents genes that were up or down regulated on microarrays but were classified as not linked to inflammatory or immune responses in the different vaccine groups.
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